Literature DB >> 6309469

Review of etoposide.

N C Phillips, R D Lauper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6309469

Source DB:  PubMed          Journal:  Clin Pharm        ISSN： 0278-2677


× No keyword cloud information.
  6 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide.

Authors:  J C Shah; J R Chen; D Chow
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

3.  High dose etoposide does not cause peripheral neuropathy.

Authors:  T J Littlewood; D P Bentley; I N McQueen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Intraarticular and intraperitoneal administration of etoposide in haematological malignancy.

Authors:  T J Littlewood; A P Lydon; F Booth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.

Authors:  B L Powell; H B Muss; R L Capizzi; M E Caponera; D R White; P J Zekan; J N Atkins; D V Jackson; F Richards; J B Craig
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.

Authors:  L M Slater; S L Murray; M W Wetzel; P Sweet; M Stupecky
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.